Efficacy and safety of a comprehensive educational antimicrobial stewardship program focused on antifungal use

J Infect. 2020 Mar;80(3):342-349. doi: 10.1016/j.jinf.2020.01.002. Epub 2020 Jan 15.

Abstract

Objective: Few data exist regarding the impact of antimicrobial stewardship programs on antifungal use. We evaluated the efficacy and safety of a comprehensive long-term antimicrobial stewardship program (ASP) focused on antifungal use.

Methods: During a 9-year period, we quarterly assessed antifungal consumption, incidence density of hospital-acquired candidemia, Candida spp. distribution, antifungal resistance, and crude death rate per 1000 occupied bed days (OBDs) of hospital-acquired candidemia. We performed segmented regression analysis of interrupted time series.

Results: A significant change in trend was observed for antifungal consumption, with a sustained reduction of -0.87% per quarter (95% confidence interval [CI], -1.36 -0.38, p < 0.001), accounting for a final reduction of -38.4%. The main reduction was produced in fluconazole, with a sustained reduction of -1.37% per quarter (95%CI, -1.96 -0.68, p<0.001). The incidence density of hospital-acquired candidemia decreased, with a change in slope of -5.06% cases per 1000 OBDs per year (95%CI, -8.23 -1.77, p = 0.009). The 14-day crude death rate per 1000 OBDs dropped from 0.044 to 0.017 (-6.36% deaths per 1000 OBDs per year; 95%CI, -13.45 -1.31, p = 0.09).

Conclusions: This ASP has succeeded in optimizing the use of antifungal with a long-lasting reduction without increasing the incidence, neither the mortality, of hospital-acquired candidemia.

Keywords: Antifungal consumption; Antimicrobial stewardship programs; Educational interviews; Hospital-acquired candidemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / adverse effects
  • Antimicrobial Stewardship*
  • Candida
  • Candidemia* / drug therapy
  • Candidemia* / epidemiology
  • Fluconazole
  • Humans
  • Incidence

Substances

  • Antifungal Agents
  • Fluconazole